36 common questions about low-dose radiation therapy for osteoarthritis, organized by topic. Every answer links to the relevant deep-dive page where you can learn more.
Low-dose radiation therapy (LDRT) is a non-surgical treatment that uses very small doses of external beam radiation — 3 Gy total in six fractions of 0.5 Gy each — to reduce the chronic joint pain and inflammation of osteoarthritis. The 2026 American Radium Society Appropriate Use Criteria provide the current U.S. consensus guidance. It is not a first-line treatment and is not a cure, but for patients who have failed conservative management it can provide meaningful pain relief lasting months to years. See our treatment overview for a full explanation.
At very low doses, radiation appears to modulate the inflammatory environment inside and around arthritic joints — calming the immune cells and cytokines that drive pain and swelling. Cartilage cells are not killed; the goal is analgesic and anti-inflammatory, not structural. More detail on the mechanism is on the overview page.
The machines and physics are identical, but the dose and goal are entirely different. Cancer radiation typically delivers 45–80 Gy to destroy tumor cells. LDRT for osteoarthritis delivers 3 Gy total — roughly 1/15th to 1/25th of a typical cancer dose — with an anti-inflammatory goal. You will not experience significant fatigue, hair loss, or immune suppression from a 3 Gy course. See the radiation safety page for the full comparison.
Low-dose radiation for musculoskeletal inflammatory conditions has been documented in the medical literature since the 1920s and 1930s. Modern standardized protocols were established in Germany in the 1990s and 2000s, and the German DEGRO national guideline has covered LDRT for osteoarthritis for over two decades. The 2026 American Radium Society Appropriate Use Criteria represent the first U.S. multispecialty formal consensus. See the evidence page for the trial history.
LDRT for osteoarthritis is not an FDA-approved indication. Linear accelerators are FDA-cleared devices, and physicians may use them for any purpose they judge medically appropriate (off-label use). Several major U.S. insurers classify LDRT as investigational partly because of the absence of a specific FDA indication. See our cost and coverage page for the insurance landscape.
LDRT for osteoarthritis is performed by radiation oncologists — physicians who specialize in using radiation to treat medical conditions. You will typically need a referral to a radiation oncology department from your primary care physician, rheumatologist, or orthopedic surgeon. Use the provider directory to find a center near you.
The 2026 ARS Appropriate Use Criteria identify generally appropriate candidates as adults over age 40 with osteoarthritis of a large joint (knee, hip, or shoulder have the strongest evidence), whose chronic pain has persisted for 3–6 months despite standard conservative management including physical therapy, oral or topical anti-inflammatory medications, and intra-articular injections. LDRT is not a first-line treatment. See the full candidacy criteria.
The ARS AUC recommends that patients under age 40 generally not be considered appropriate candidates. The reason is quantitative: radiation-induced solid tumors appear 10–60 years after exposure; for a young patient with many remaining treatment-years ahead and a non-life-threatening condition, the risk-benefit calculation does not favor radiation when other options remain. There is no upper age limit. See the candidacy page for age-related context.
The Kellgren-Lawrence (KL) scale grades osteoarthritis severity on X-ray from 0 (normal) to 4 (severe). The ARS AUC considers LDRT appropriate for KL grades 1 through 3 as the primary range. KL 4 patients may have a lower response rate, but the ARS AUC does not exclude them — refractory KL 4 patients who are not surgical candidates may still be appropriate candidates. Details on the candidacy page.
LDRT is not used in joints that have already undergone arthroplasty — the treatment targets inflammatory processes in native joint tissue. If one joint is replaced, LDRT may still be appropriate for the contralateral native joint. See candidacy criteria for more.
Metal implants such as surgical plates, screws, or prior partial replacement components do not preclude LDRT in most cases. The radiation planning process accounts for the presence of metal, and dosimetric adjustments are made as needed. The treating radiation oncologist will review your imaging and surgical history to confirm suitability. See candidacy for the full list of considerations.
Response rates may be lower in KL 4 disease, but the ARS AUC does not exclude KL 4 patients. A refractory KL 4 patient who has exhausted all conservative management and is not a surgical candidate may still be an appropriate LDRT candidate — the expectation of benefit is lower, and this should be discussed openly before treatment. See candidacy criteria.
LDRT for osteoarthritis is specific to the inflammatory-degenerative process of osteoarthritis. Rheumatoid arthritis and psoriatic arthritis are systemic autoimmune diseases driven by immune dysregulation — a fundamentally different mechanism that requires disease-modifying antirheumatic drug (DMARD) therapy. The ARS AUC does not endorse LDRT for RA or psoriatic arthritis. See who qualifies.
The strongest clinical evidence is for knee, hip, and shoulder osteoarthritis — these are the primary joints covered by the ARS AUC and the German DEGRO guideline, with the knee having the most randomized trial data. Good European series also support hand, finger, thumb (CMC), and foot and ankle joints. The spine has limited published data and the ARS AUC recommends caution.
The ARS AUC explicitly recommends caution for spinal osteoarthritis due to limited published data in this anatomical region. Spinal LDRT is not currently an endorsed application under the 2026 ARS AUC, and most U.S. providers focus on peripheral joints. See the spine page for what the evidence does and does not support.
A standard LDRT course delivers 3 Gy total — given as six fractions of 0.5 Gy each, two to three times per week over approximately two weeks. For context, cancer treatment typically delivers 45–80 Gy. The 3 Gy delivered to a joint field is very small in absolute terms. See the radiation safety page for the full dose comparison.
A CT scan delivers a low effective whole-body dose (roughly 0.002–0.014 Gy depending on the scan type), spread across many organs. LDRT delivers 3 Gy concentrated in a single joint field — a higher local dose to the treated area than any routine diagnostic scan, but targeting a very small volume of tissue. More on the safety page.
No published case reports of secondary malignancy attributable to LDRT for osteoarthritis exist. The ARS AUC calculated the estimated additional secondary malignancy risk at approximately 0.06% for a 70-year-old patient — about 1 in 1,700. That must be weighed against the burden of chronic joint pain and the risks of long-term NSAID use. Full discussion on the radiation safety page.
The ARS AUC calculated the estimated additional secondary malignancy risk at approximately 0.06% for a 70-year-old patient receiving 3 Gy total LDRT with approximately 2% of red bone marrow in the treatment field. This estimate uses the linear no-threshold (LNT) model. The 0.06% figure is very small relative to background cancer rates (~40% lifetime cancer risk in the U.S. population). See the radiation safety page for full context.
A history of cancer requires case-by-case clinical judgment. A radiation oncologist can weigh the risks of additional radiation exposure against the benefit of treating joint pain in the context of your specific cancer history and current health status. LDRT for OA is not appropriate for patients with active malignancy. See radiation safety and candidacy criteria.
No. External beam radiation passes through the body and does not make your tissues or fluids radioactive. You can be around family members — including children and pregnant women — immediately after each session. There are no precautions needed after leaving the treatment room. See the radiation safety page.
No published data demonstrate a negative effect of prior LDRT on subsequent joint replacement outcomes. The 3 Gy total dose used for OA is far below doses that cause radiation-associated tissue injury. If LDRT provides years of symptom relief and surgery is eventually needed, the prior LDRT course should not complicate the procedure or healing. See LDRT vs. knee replacement for more context.
Yes — older adults are, in fact, the most appropriate target population for LDRT. The treatment requires no anesthesia, no recovery period, and does not interact with most medications. Many published series have a median patient age above 65. The cancer risk calculation actually favors older patients because the latency window for radiation-induced malignancy is shorter relative to remaining lifespan. See candidacy criteria.
A typical course is six sessions delivering 0.5 Gy each (3 Gy total), usually two or three sessions per week over two to three weeks. Some protocols use three sessions of 1 Gy each, though the ARS AUC notes the evidence is stronger for the 0.5 Gy/fraction protocol. See the side effects and timing page for the full treatment timeline.
Each treatment session typically takes 10–20 minutes in the department, of which only 2–5 minutes is actual beam-on time. The remainder is positioning the joint correctly under the machine. Most patients drive themselves to each session. More on what to expect on the side effects page.
The radiation itself is completely painless and passes through the body silently. There are no needles, injections, or implants. A temporary pain flare in the first few days after beginning treatment is possible and is reported in a minority of patients — if it occurs, it typically resolves within a week. See the side effects page for a full account of what to expect. Watch: what to expect at your visits (1-minute video).
Response patterns vary. Some people notice meaningful change within 4–6 weeks of completing treatment; others continue to improve over 2–3 months. The anti-inflammatory effect builds gradually. In published series, most responders see peak benefit at approximately 3 months post-treatment. Details on the side effects and timing page.
When LDRT helps, relief often lasts 6–24 months from a single course. The Makarova 10-year randomized follow-up found significantly less structural X-ray deterioration in the LDRT group at a decade. The German DEGRO guideline describes treatment as producing relief in 60–90% of patients. See the evidence page for the full data.
Yes. Re-treatment with LDRT after relapse is described in the European literature and is considered acceptable in appropriate patients because the cumulative dose remains very low. The interval between courses and candidacy for re-treatment is a clinical judgment made by the treating radiation oncologist. See side effects and timing.
At these doses, acute side effects are minimal. The DEGRO guideline describes the treatment as producing relief in 60–90% of patients with almost no acute side effects. A temporary pain flare in the first few days is possible; skin reactions at doses below 0.5 Gy per session are uncommon. The fatigue, nausea, and immune suppression associated with high-dose cancer radiation do not occur at these doses. Full detail on the side effects page.
No. LDRT does not produce the fatigue or tissue reactions that require recovery time. Most patients drive themselves to each session and resume normal activities immediately afterward — including work and moderate physical activity. There are no restrictions on being around other people. See side effects and timing.
Coverage varies significantly by insurer, plan, and region. Several major insurers — including Blue Shield of California and Blue Cross Blue Shield of Massachusetts — currently classify LDRT for osteoarthritis as investigational and do not routinely cover it. Medicare and some regional plans may cover it when medically necessary, though prior authorization is often required. See our cost and coverage page for the full landscape.
Medicare coverage depends on how the treatment is billed and whether clinical documentation supports medical necessity. LDRT for osteoarthritis does not have a specific Medicare National Coverage Determination — coverage is adjudicated at the local carrier level. Some Medicare beneficiaries have had LDRT covered; others have not. See the cost and coverage page for guidance.
When an insurer classifies LDRT as investigational, it means they have reviewed the published evidence and determined it does not yet meet their threshold for routine coverage. This does not mean the treatment is experimental in a clinical sense — many established treatments carry investigational classifications for years after broad clinical adoption. In practice, prior authorization denial is common and appeals processes are often needed. Full explanation on the cost and coverage page.
In most cases, yes. Most radiation oncology departments require a referring physician order before scheduling a consultation. Your primary care physician, rheumatologist, or orthopedic surgeon can write this referral. Some programs accept self-referrals or can facilitate a referral through their patient navigation team. Use the provider directory to find a center and ask about their referral process.
Use the interactive provider directory to search by state. All listed providers have been verified as offering LDRT for osteoarthritis. If you do not see a provider near you, check neighboring states — LDRT availability is expanding and new programs are added regularly.
Medically reviewed by: Robert Warren Floyd, M.D., Ph.D. — Resident Physician, Radiation Oncology, The University of Texas MD Anderson Cancer Center. Last reviewed: September 8, 2026. Independent personal project — not affiliated with or endorsed by MD Anderson Cancer Center. Funding & independence disclosure.
This content is for education only and is not medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.